vs
美泰（MAT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
美泰的季度营收约是Revvity的1.1倍（$862.2M vs $772.1M），Revvity净利率更高（12.7% vs 7.1%，领先5.7%），Revvity同比增速更快（5.9% vs 4.3%），Revvity自由现金流更多（$161.8M vs $-88.1M），过去两年Revvity的营收复合增速更高（9.0% vs -10.6%）
美泰是美国知名玩具及娱乐企业，旗下影视制作部门美泰影业运营时间为2018年9月6日至2025年6月2日。其前身为2013年10月16日成立的美泰Playground Productions，更早可追溯至美泰娱乐、美泰工作室等集团原有娱乐业务品牌。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MAT vs RVTY — 直观对比
营收规模更大
MAT
是对方的1.1倍
$772.1M
营收增速更快
RVTY
高出1.5%
4.3%
净利率更高
RVTY
高出5.7%
7.1%
自由现金流更多
RVTY
多$249.9M
$-88.1M
两年增速更快
RVTY
近两年复合增速
-10.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $862.2M | $772.1M |
| 净利润 | $61.0M | $98.4M |
| 毛利率 | 44.9% | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 7.1% | 12.7% |
| 营收同比 | 4.3% | 5.9% |
| 净利润同比 | 251.4% | 3.9% |
| 每股收益（稀释后） | $0.20 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MATRVTY
| Q1 26 | $862.2M | — | ||
| Q4 25 | $1.8B | $772.1M | ||
| Q3 25 | $1.7B | $698.9M | ||
| Q2 25 | $1.0B | $720.3M | ||
| Q1 25 | $826.6M | $664.8M | ||
| Q4 24 | $1.6B | $729.4M | ||
| Q3 24 | $1.8B | $684.0M | ||
| Q2 24 | $1.1B | $691.7M |
净利润MATRVTY
| Q1 26 | $61.0M | — | ||
| Q4 25 | $106.2M | $98.4M | ||
| Q3 25 | $278.4M | $46.7M | ||
| Q2 25 | $53.4M | $53.9M | ||
| Q1 25 | $-40.3M | $42.2M | ||
| Q4 24 | $140.9M | $94.6M | ||
| Q3 24 | $372.4M | $94.4M | ||
| Q2 24 | $56.9M | $55.4M |
毛利率MATRVTY
| Q1 26 | 44.9% | — | ||
| Q4 25 | 45.9% | — | ||
| Q3 25 | 50.0% | 53.6% | ||
| Q2 25 | 50.9% | 54.5% | ||
| Q1 25 | 49.4% | 56.5% | ||
| Q4 24 | 50.7% | — | ||
| Q3 24 | 53.1% | 56.3% | ||
| Q2 24 | 49.2% | 55.7% |
营业利润率MATRVTY
| Q1 26 | — | — | ||
| Q4 25 | 8.0% | 14.5% | ||
| Q3 25 | 21.9% | 11.7% | ||
| Q2 25 | 7.7% | 12.6% | ||
| Q1 25 | -6.4% | 10.9% | ||
| Q4 24 | 9.6% | 16.3% | ||
| Q3 24 | 26.5% | 14.3% | ||
| Q2 24 | 7.7% | 12.4% |
净利率MATRVTY
| Q1 26 | 7.1% | — | ||
| Q4 25 | 6.0% | 12.7% | ||
| Q3 25 | 16.0% | 6.7% | ||
| Q2 25 | 5.2% | 7.5% | ||
| Q1 25 | -4.9% | 6.4% | ||
| Q4 24 | 8.6% | 13.0% | ||
| Q3 24 | 20.2% | 13.8% | ||
| Q2 24 | 5.3% | 8.0% |
每股收益（稀释后）MATRVTY
| Q1 26 | $0.20 | — | ||
| Q4 25 | $0.32 | $0.86 | ||
| Q3 25 | $0.88 | $0.40 | ||
| Q2 25 | $0.16 | $0.46 | ||
| Q1 25 | $-0.12 | $0.35 | ||
| Q4 24 | $0.40 | $0.77 | ||
| Q3 24 | $1.09 | $0.77 | ||
| Q2 24 | $0.17 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $866.0M | $919.9M |
| 总债务越低越好 | $2.3B | — |
| 股东权益账面价值 | $2.1B | $7.3B |
| 总资产 | $6.3B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.11× | — |
8季度趋势，按日历期对齐
现金及短期投资MATRVTY
| Q1 26 | $866.0M | — | ||
| Q4 25 | $1.2B | $919.9M | ||
| Q3 25 | $691.9M | $931.4M | ||
| Q2 25 | $870.5M | $991.8M | ||
| Q1 25 | $1.2B | $1.1B | ||
| Q4 24 | $1.4B | $1.2B | ||
| Q3 24 | $723.5M | $1.2B | ||
| Q2 24 | $722.4M | $2.0B |
总债务MATRVTY
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.3B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.3B | — |
股东权益MATRVTY
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.2B | $7.3B | ||
| Q3 25 | $2.3B | $7.4B | ||
| Q2 25 | $2.2B | $7.6B | ||
| Q1 25 | $2.1B | $7.6B | ||
| Q4 24 | $2.3B | $7.7B | ||
| Q3 24 | $2.3B | $7.9B | ||
| Q2 24 | $2.0B | $7.9B |
总资产MATRVTY
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.6B | $12.2B | ||
| Q3 25 | $6.6B | $12.1B | ||
| Q2 25 | $6.2B | $12.4B | ||
| Q1 25 | $6.2B | $12.4B | ||
| Q4 24 | $6.5B | $12.4B | ||
| Q3 24 | $6.5B | $12.8B | ||
| Q2 24 | $5.9B | $13.4B |
负债/权益比MATRVTY
| Q1 26 | 1.11× | — | ||
| Q4 25 | 1.04× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 1.08× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.03× | — | ||
| Q3 24 | 1.01× | — | ||
| Q2 24 | 1.18× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-88.1M | $161.8M |
| 自由现金流率自由现金流/营收 | -10.2% | 21.0% |
| 资本支出强度资本支出/营收 | 7.6% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流MATRVTY
| Q1 26 | — | — | ||
| Q4 25 | $796.6M | $182.0M | ||
| Q3 25 | $72.0M | $138.5M | ||
| Q2 25 | $-300.1M | $134.3M | ||
| Q1 25 | $24.8M | $128.2M | ||
| Q4 24 | $862.1M | $174.2M | ||
| Q3 24 | $155.8M | $147.9M | ||
| Q2 24 | $-252.9M | $158.6M |
自由现金流MATRVTY
| Q1 26 | $-88.1M | — | ||
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M |
自由现金流率MATRVTY
| Q1 26 | -10.2% | — | ||
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% |
资本支出强度MATRVTY
| Q1 26 | 7.6% | — | ||
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% |
现金转化率MATRVTY
| Q1 26 | — | — | ||
| Q4 25 | 7.50× | 1.85× | ||
| Q3 25 | 0.26× | 2.97× | ||
| Q2 25 | -5.62× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 6.12× | 1.84× | ||
| Q3 24 | 0.42× | 1.57× | ||
| Q2 24 | -4.45× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MAT
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
